image
Healthcare - Medical - Devices - NASDAQ - US
$ 82.93
-0.778 %
$ 32.5 B
Market Cap
62.35
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one DXCM stock under the worst case scenario is HIDDEN Compared to the current market price of 82.9 USD, DexCom, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one DXCM stock under the base case scenario is HIDDEN Compared to the current market price of 82.9 USD, DexCom, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one DXCM stock under the best case scenario is HIDDEN Compared to the current market price of 82.9 USD, DexCom, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart DXCM

image
$95.0$95.0$90.0$90.0$85.0$85.0$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
4.03 B REVENUE
11.34%
600 M OPERATING INCOME
0.38%
576 M NET INCOME
6.41%
990 M OPERATING CASH FLOW
32.20%
-208 M INVESTING CASH FLOW
59.09%
-735 M FINANCING CASH FLOW
-130.63%
1.04 B REVENUE
-6.96%
134 M OPERATING INCOME
-29.22%
105 M NET INCOME
-30.52%
184 M OPERATING CASH FLOW
-39.02%
100 M INVESTING CASH FLOW
132.99%
12.5 M FINANCING CASH FLOW
881.25%
Balance Sheet DexCom, Inc.
image
Current Assets 4.3 B
Cash & Short-Term Investments 2.58 B
Receivables 1.03 B
Other Current Assets 688 M
Non-Current Assets 2.18 B
Long-Term Investments 119 M
PP&E 1.4 B
Other Non-Current Assets 661 M
39.78 %15.94 %10.62 %21.63 %10.20 %Total Assets$6.5b
Current Liabilities 2.93 B
Accounts Payable 345 M
Short-Term Debt 1.23 B
Other Current Liabilities 1.36 B
Non-Current Liabilities 1.45 B
Long-Term Debt 1.36 B
Other Non-Current Liabilities 89.4 M
7.88 %28.00 %31.03 %31.05 %Total Liabilities$4.4b
EFFICIENCY
Earnings Waterfall DexCom, Inc.
image
Revenue 4.03 B
Cost Of Revenue 1.57 B
Gross Profit 2.47 B
Operating Expenses 1.87 B
Operating Income 600 M
Other Expenses 23.8 M
Net Income 576 M
5b5b4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m004b(2b)2b(2b)600m(24m)576mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
61.14% GROSS MARGIN
61.14%
14.88% OPERATING MARGIN
14.88%
14.29% NET MARGIN
14.29%
27.40% ROE
27.40%
8.89% ROA
8.89%
10.20% ROIC
10.20%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis DexCom, Inc.
image
700m700m600m600m500m500m400m400m300m300m200m200m100m100m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 576 M
Depreciation & Amortization 218 M
Capital Expenditures -359 M
Stock-Based Compensation 170 M
Change in Working Capital 0
Others 25.2 M
Free Cash Flow 631 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets DexCom, Inc.
image
Wall Street analysts predict an average 1-year price target for DXCM of $113 , with forecasts ranging from a low of $89 to a high of $145 .
DXCM Lowest Price Target Wall Street Target
89 USD 7.32%
DXCM Average Price Target Wall Street Target
113 USD 35.96%
DXCM Highest Price Target Wall Street Target
145 USD 74.85%
Price
Max Price Target
Min Price Target
Average Price Target
15015014014013013012012011011010010090908080707060605050Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership DexCom, Inc.
image
Sold
0-3 MONTHS
2.28 M USD 4
3-6 MONTHS
9.96 M USD 7
6-9 MONTHS
806 K USD 4
9-12 MONTHS
296 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
2 Stocks to Buy on the Dip and Hold for 10 Years One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. One way to apply this wisdom is to look for companies that have lagged the market recently but still appear to be excellent long-term investment opportunities. fool.com - 2 weeks ago
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year? Here is how DexCom (DXCM) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year. zacks.com - 2 weeks ago
3 Reasons Growth Investors Will Love DexCom (DXCM) DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com - 2 weeks ago
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids Shares of Dexcom, Tandem Diabetes and Insulet skidded Tuesday on a proposal that would cut Medicare reimbursements for wearable diabetes tech. investors.com - 2 weeks ago
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time. SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and wil. businesswire.com - 2 weeks ago
Here's Why DexCom (DXCM) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 3 weeks ago
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 3 weeks ago
DXCM's Access Gains and Operational Strength Offset Margin Pressures DXCM rides on record patient growth and T2D access gains, but margin pressure and FDA scrutiny cloud the outlook. zacks.com - 1 month ago
Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025 SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc., the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 400 healthcare professionals and people with Type 2 diabetes across the United States. During the conference, Dexcom will p. businesswire.com - 1 month ago
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and purpo. businesswire.com - 1 month ago
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws. globenewswire.com - 1 month ago
Jefferies' high conviction US stocks for the summer: Nvidia among top picks Global brokerage firm Jefferies shared their top 28 US stocks in the “highest-conviction Buy rated” stocks. Jefferies shared the list as the US market is coming fresh off its best month in May since November 2023. invezz.com - 1 month ago
8. Profile Summary

DexCom, Inc. DXCM

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 32.5 B
Dividend Yield 0.00%
Description DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Contact 6340 Sequence Drive, San Diego, CA, 92121 https://www.dexcom.com
IPO Date April 14, 2005
Employees 10200
Officers Mr. Kevin Ronald Sayer Executive Chairman, Chief Executive Officer & President Mr. Michael Jon Brown Executive Vice President & Chief Legal Officer Mr. Sean Christensen Vice President of Finance and Investor Relations Mr. Matthew Dolan Executive Vice President of Strategy, Corporate Development & Dexcom Labs Ms. Leverne Marsh Executive Vice President of Marketing Ms. Sadie M. Stern Executive Vice President & Chief Human Resources Officer Mr. Jereme M. Sylvain CPA Executive Vice President, Chief Financial Officer & Chief Accounting Officer Mr. Donald M. Abbey Executive Vice President of Global Business Services, IT, Quality & Regulatory Affairs Mr. Jacob Steven Leach Executive Vice President & Chief Operating Officer Mr. Girish Naganathan Executive Vice President & Chief Technology Officer